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ABSTRACT
Background: Drug-related morbidity contributes to every tenth unplanned  hospital 
admission in older patients. A way to address this problem is to identify and 
minimize potentially inappropriate prescribing (PIP). Two important types of PIP 
are the use of contraindicated or excessively dosed drugs in patients with renal 
impairment and drug-disease interactions, where a drug worsens a concomitant 
disease. It is largely unknown how commonly older patients (≥ 65) are exposed to 
these two types of PIP. Similarly, there is insufficient knowledge on how general 
practitioners (GPs) and nurses in primary care should address PIP in their older 
patients. One important step in understanding how to address PIP is to investigate 
GPs’ and nurses’ views on PIP and medication reviews.
Aim: 1) To increase knowledge on how commonly older patients in primary care 
are exposed to PIP in relation to renal function and drug-disease interactions; 2) To 
examine if an intervention on medication reviews combining several evidence-
based educational strategies is a valuable measure to address PIP in primary care; 
and 3) To understand GPs’ and nurses’ views on PIP and medication reviews.
Material and methods: Two cross-sectional population-based studies (I+II) in patients 
aged ≥65 in primary care in Stockholm County were performed. Drug dispense was 
assessed during one year. PIP in relation to renal function was assessed in patients 
with chronic kidney disease stage 3 (n=30 372) or 4 (n=2161)  according to CKD-EPI 
formula (I). Drug-disease interactions were analyzed among 336 295 patients. PIP 
was addressed in a cluster-randomized controlled trial including 69 primary care 
practices (III). The multifaceted educational intervention targeted GPs and nurses, 
with the aim to promote medication reviews in accordance with a new regulation, 
thus reduce PIP and unplanned healthcare use. Data (I-III) were derived from 
regional and national registers (diagnoses, drugs, healthcare use) and SCREAM 
database (creatinine). Qualitative data were collected after each educational session 
and explored with thematic analysis (IV). 
Results: I: Contraindicated medicines were used by 9% of patients with chronic 
kidney disease stage 3 compared to 38% with stage 4, and excessive dosing was 
present in 43% vs. 58%, respectively. II: Drug-disease interactions were found in 
10.8 % of older adults, the most common was hypertension/NSAID. I+II: A limited 
number of potentially inappropriate medicines explained the majority of PIP, such 
as NSAIDs (I + II) and drugs acting on the renin-angiotensin-aldosterone system 
(I). III: Neither PIP nor unplanned healthcare decreased after a multifaceted edu-
cational intervention in primary care. IV: A possible explanation for this result is 
the complexity of prescribing in older patients, as expressed by GPs and nurses. 
Conclusions: In patients with impaired renal function, excessive dosing was more 
common than the use of contraindicated medicines. Drug-disease interactions 
were less common than PIP in relation to renal function. Both types of PIP seem 
 manageable as only a few medicines are implicated. Medication reviews that 
address PIP in its entirety are difficult to implement in primary care and may not 
improve prescribing in older patients. According to GPs and nurses, the complexity 
of PIP is a major challenge. Their efforts to improve prescribing are undermined 
by this complexity. In view of the potential harm of PIP in older patients, it is 
crucial to continue research on how it may be decreased. 
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11 PROLOGUE
She walked slowly from the waiting room into my office. She was paler and more 
breathless than the last time I had met her two months ago. Sitting down heavily 
on the chair, she said: “I feel so tired, doctor. My sleeping pills only work for two 
hours and then I wake up. Isn’t there anything stronger? And I have to go to the 
toilet several times during the night. You know, my husband died in February and 
I feel alone, I am afraid to fall and lie on the floor the whole night. Who would 
notice?”. I listened carefully, thinking by myself that – once again – the consulta-
tion time would not be sufficiently long to thoroughly evaluate her complaints... 
I knew that she suffered from heart failure and diabetes, urinary incontinence after 
having given birth to three children, was obese, had smoked but had been able 
to quit, had chronic back pain, and that her daughter had phoned me recently to 
express her concerns about her mother getting forgetful. According to the electronic 
patient journal she was treated with 11 drugs, among others zopiclone, enalapril, 
furosemide, metformin and paracetamol. I started to examine her, took a blood 
pressure and pulse, and deemed them to be normal. Were her ankles more swollen 
than the last time we had met? I suspected that her complaints were partly due to 
her heart failure, but wondered if she also was depressed? Did she really take all 
the medicines on her list? Could her complaints be due to side effects? 
22 BACKGROUND
2.1 The older patient
Older people are a growing population group. In 2050, every fourth person is 
expected to be 65 or older (2). Drug treatment is one reason to why more and more 
people reach old age. The benefits of drugs in older patients are numerous. Drugs 
reduce symptoms, such as for example antidepressants (3). Drugs treat risk factors, 
such as antihypertensives (4). Drugs prevent complications of diseases, such as 
warfarin reducing the risk of stroke in patients with atrial fibrillation. Drugs may 
delay death, such as antibiotics, or increase survival rates, such as ACE-inhibitors 
in patients with heart failure (5). Moreover, drugs may improve poor quality of 
life, such as opioids reducing pain. 
Parallel with age, the number of diseases increase. Multimorbidity, defined as the 
presence of two or more diseases at the same time, is more common than suffering 
from a single disease (6). Problematically, prescribing guidelines generally focus on 
single diseases (7, 8). Drug treatment according to guidelines in a 72 year old male 
obese patient with heart failure after myocardial infarction, diabetes and benign 
prostate hyperplasia would add up to at least 9 medicines administered as several 
doses at different time points during the day (such as: acetyl salicylic acid, statin, 
enalapril, furosemide, betablocker, metformin, glimepiride, alfuzosin, finasterid), 
which illustrates that polypharmacy is the rule rather than the exception in older 
age (7). In western countries, every third older adult is treated with five or more 
substances on a regular basis (9, 10). 
The more drugs a person uses, the higher the risk for adverse drug reactions and 
consequently drug-related morbidity. Older patients are particularly prone to expe-
riencing adverse drug reactions. This is due to age-related pharmacokinetic and 
pharmacodynamic changes. Pharmacokinetics relate to the absorption, distribution 
and elimination of a substance, whereas pharmacodynamics refer to the  physiologic 
effects of a drug (11). An example of pharmacokinetic changes in older age is 
the decrease of renal plasma flow and glomerular filtration rate which favors 
the accumulation of renally cleared drugs such as ACE-inhibitors. Examples for 
pharmacodynamic changes are the higher sensitivity for benzodiazepines in older 
compared to younger patients favoring side effects such as dizziness and sedation; 
and the impairment of blood pressure regulation due to increased vessel stiffness 
making falls more likely.
32.2 The complexity of medical care in older patients
Drug-related morbidity contributes to every tenth unplanned hospital admission 
in older patients (12, 13). The verb “contributes” instead of “causes” accounts 
for the uncertainty of a causal relationship between the exposure to a (potentially 
inappropriate, thus harmful) drug and an (undesired) adverse drug reaction (14). 
The clinician who evaluates an older patient will only rarely be sure if a symp-
tom or abnormal laboratory test is caused by a drug or the underlying disease. An 
 example is hyponatremia in patients with heart failure and diuretics. It is crucial 
to be aware of this complexity. Figure 1 illustrates the relationship between mor-
bidity, drug use, PIP and unplanned healthcare in older patients.
(multi-) morbidity 
drug use
potentially
inappropriate
prescribing
unplanned
healthcare
Figure 1. Relationship between (multi-) morbidity, drug use, potentially inappropriate 
prescribing and unplanned healthcare in older patients.
(Multi-) morbidity leads to drug use. The more drugs are used, the higher the risk for 
PIP which in its turn may cause new symptoms and entail the prescription of more 
drugs (15) (16), cause unplanned healthcare or further morbidity. Multimorbidity 
itself is also associated with unplanned healthcare, and vice versa may inpatient 
healthcare cause illness (such as falls (17) or nosocomial infections (18)), or lead 
to the prescription of more (appropriate and inappropriate) drugs. Even if drugs 
are used in a rational way they may cause unplanned healthcare (for example first-
time allergic reaction to antibiotics).
42.3 Primary care and its key role in the care of older 
patients
Older patients with many comorbidities are often treated and followed up in primary 
health care (19). Primary health care in Sweden is provided by public and private 
general practices which both are publicly financed (20). Patients may consult a 
 specialist without being referred from a GP, as primary care does not have a gate-
keeper function (21). However, when people experience a health problem, they first 
of all consult a GP or nurse at a primary care practice. In Stockholm County, nine 
out of ten adults aged ≥ 65 are registered at a practice and meet a GP on average 
3.8 times a year (22). All residents have access to health care for low patient fees. 
A considerable amount of prescribing to older patients is performed by primary 
care professionals (figure 2). Still, older patients even receive prescriptions from 
hospitals or specialists other than GPs (23). Formally, Swedish primary care is not 
responsible for the patient’s drug list in its entireness (24).
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Figure 2. Who prescribes to older patients registered with a primary care practice in 
Stockholm County? Each bar corresponds to a primary care practice. (Data extracted 
from Stockholm County’s Regional healthcare data Warehouse (25)).
2.4 What is potentially inappropriate prescribing, and 
why is it problematic?
Since the early 1990’s up to now, the significance of the term “potentially  inappropriate 
prescribing” has undergone a transformation. Initially, PIP referred to misprescrib-
ing and the use of “too many inappropriate drugs”. The first criteria for PIP, the 
Beers Criteria from 1991, focused on misprescribing. These criteria included 30 
5indicators. Nineteen indicators related to drugs that should be avoided such as 
long-acting benzodiazepines, and eleven to inappropriate drug dosages,  frequencies 
or durations of drug treatment such as “ranitidine at dose > 300mg/day and dura-
tion > 12 weeks” (26). Beers criteria were developed in the US based on expert 
opinions and thus do not entirely match European settings. Subsequently, other 
criteria were developed in different countries (27, 28) or original criteria were 
updated (29-31), reflecting a more holistic view on PIP. 
Besides misprescribing even overprescribing and underprescribing (also called 
“potential prescribing omissions”) are now considered potentially inappropriate 
(27). In particular underprescribing has gained increased interest, as unplanned 
hospital admissions have been associated with under- rather than misprescribing 
(32). The term “appropriate use of polypharmacy” illustrates that polypharmacy 
does not per se have a negative significance (33). From a clinical point of view 
this holistic approach seems valid. 
PIMs may be categorized into different groups: 1) drugs that should be avoided 
(such as longacting benzodiapzepines, drugs with anticholinergic effects) 2) drugs 
that are inappropriate in impaired renal function (such as NSAIDs), 3) drug-drug 
interactions (such as warfarin and paracetamol), and 4) drug-disease interactions 
(such as betablocking agents in patients with asthma). Of note, there is overlap 
between the different PIM groups. For example, NSAIDs are contraindicated in 
severely impaired renal function (group 2), may interact with warfarin and increase 
risk for bleeding (group 3), and may worsen heart failure (group 4).
PIP criteria may be explicit or implicit (27, 34). Explicit criteria are developed 
based on consensus processes, literature searches and expert opinions. They com-
prise drug classes, drug dosages or drug combinations that should be avoided due 
to an increased risk for adverse effects, such as long-acting benzodiazepines. One 
important disadvantage of explicit criteria is that they do not consider the burden 
of comorbidity frequently present in older patients. Examples for explicit criteria 
are the abovementioned American Beers criteria (29), the German PRISCUS list 
(35), the Canadian Mc Leod criteria (36), the Irish STOPP/START criteria (37), 
the Swedish criteria (1, 38) or the European FORTA criteria (39). 
Implicit indicators rely on the judgment of the clinician, and PIP is assessed at an 
individual level. One example is the Medication Appropriateness Index (MAI) 
(40), a weighted appropriateness score assessing several prescribing dimensions, 
such as the indication of drug treatment, drug dose and drug-disease interactions. 
There are two important reflections in relation to different PIP criteria.
First, they are a collection of PIMs, drug combinations, and drug-disease com-
binations, but only few of them have been tested prospectively in older patients. 
In other words, it is uncertain to which extent adverse drug reactions will be pre-
6vented if older patients’ drug treatment follows the criteria. One exception are 
the Irish STOPP/START criteria containing 114 indicators whereof 80 refer to 
 misprescribing (STOPP criteria) and 34 to underprescribing (START criteria) (37). 
Clinical outcomes seem to improve when drug treatment is optimized following 
STOPP/START criteria (41-43). Moreover, the complementary use of Beers and 
STOPP/START criteria has shown to have modest predictive validity in relation to 
the detection of adverse drug reactions and unplanned health care consumption (44). 
Second, GPs face high demands of efficiency. They may find that extensive criteria 
are too detailed and time-consuming (45). Studies evaluating the clinical impact of 
PIP criteria often include pharmacist support, a resource which is rarely available 
in primary care. Positive results shown in studies including pharmacist support 
may therefore not simply be extrapolated to the primary care setting.
Table 1. Similarities and differences between the Swedish criteria (version 2010) 
and STOPP-START criteria (version 2015)
Swedish criteria STOPP-START criteria
Si
m
ila
rit
ie
s Overall construction 
of criteria
Two sections “stopp” (misprescribing) and “start”  
(mainly underprescribing)
Drug-disease 
interactions
No separate list of drugs that may worsen a pre-existing condition 
(quoted from (48))  
(drug-disease interactions)
D
iff
er
en
ce
s
Underlying 
approach
Rather pharmacological (indi-
cators are grouped by pharma-
cological characteristics, for 
example separate chapter on 
drug-drug interaction)
Rather clinical (indicators are 
grouped by morbidity, for example 
“cardiovascular system criteria”)
Focus Focus on “drugs to avoid” 
without taking into account 
morbidity
Focus on drug treatment in  relation 
to morbidity
Validity Not prospectively validated Validated in several studies
PIP in relation to 
renal function
Separate list of 29 drugs/drug 
groups, but recommendations 
do not include concrete levels 
of renal function
Chapter E in STOPP includes 
6 drugs that are inappropriate 
below a concrete level of renal 
function
Specific 
recommendations
“concomitant use of potassium 
and potassium-sparing agents 
(for example, amilorid or 
spironolactone), if there are no 
special reasons for this com-
bination (intolerance against 
spironolactone or amilorid)”
“Aldosterone antagonists (e.g. 
spironolactone, eplerenone) with 
concurrent potassium-conserving 
drugs (e.g. ACEI’s, ARB’s, amiloride, 
triamterene) without monitoring of 
serum potassium (risk of dangerous 
hyperkalemia i.e. > 6.0 mmol/l – 
serum K should be monitored regu-
larly, i.e. at least every 6 months).”
PIP potentially inappropriate prescribing, ACEI Angiotensin-converting-enzyme inhibitor, ARB 
Angiotensin II Receptor Blockers.
72.4.1 The Swedish criteria of potentially inappropriate 
prescribing 
In 2004, the Swedish National Board of Health and Welfare released the first 
 version of the Swedish criteria of PIP (46) based on American Beers Criteria (26) 
and Canadian Mc Leod Criteria (36). This list was updated twice in 2010 (1, 38) and 
2017 (47). The Swedish criteria comprise two sections, namely a misprescribing 
and an underprescribing section. For similarities and differences between the 
Swedish criteria and STOPP-START criteria see table 1.
Contrary to Beers Criteria, neither the Swedish criteria nor STOPP-START  criteria 
include a specific list of drug-disease interactions defined as “drugs that may 
worsen a pre-existing condition” (quoted from (48).
2.4.2 Potentially inappropriate prescribing in relation to 
renal function
Impaired renal function plays a major role in the context of adverse drug reactions 
(49, 50). Some PIP criteria (29, 37) include a section on PIP in impaired renal func-
tion, but the specific substances differ substantially. For example, Beers’ Criteria 
list 20 substances that should be dose-reduced or are contraindicated in renal 
impairment, yet a commonly used drug like metformin is not part of this list (29). 
Irish STOPP/START criteria include only six contraindicated drugs whereof one is 
metformin that should not be given below an eGFR of 30ml/min (37). Moreover, 
there are substantial differences regarding recommendations on drug dosing (51). 
Surprisingly, there is no internationally recognized list of renal PIMs. 
From a clinical point of view, it seems important that the definition of renal PIMs 
not only includes drug dosing and contraindicated drugs (as is the case in the 
abovementioned criteria) but also: 1) follow-up of electrolytes and/or renal function 
(such as spironolactone) 2) nephrotoxicity (such as aminoglycosides), 3) harm by 
active metabolites (such as morphine), and 4) lack of effectiveness in highly impaired 
renal function (such as hydrochlorothiazide).
In order to create a list of renal PIMs that takes into account the different catego-
rizations presented above, we compared seven literature sources (52-58). Finally, 
the attempt to  create a synthetic list was abandoned due to two findings: 1) the 
majority of drugs included in the final list are only rarely used in primary care, 2) 
there is only limited overlap between the literature sources (52-58), implying that 
there is no clear-cut and generally applicable definition of renal PIP. 
In Stockholm County, clinicians use “Janusmed Drugs and Renal function”, a 
 comprehensive knowledgebase with evidence based recommendations on drug use 
in the context of impaired renal function. Janusmed relies on Finnish Renbase® and 
is integrated in the electronic medical record (see chapter 4.3.1 for details) (59). 
82.4.3 Drug-disease interactions
According to Pugh et al (48), a drug-disease interaction is present when a drug 
prescribed to treat one of a patient’s diseases at the same time may “worsen a 
pre-existing condition” (quoted from (48)). One example for such a DDSI is the 
use of NSAIDs against osteoarthritic pain in a patient who also has heart failure. 
This interaction may be critical as NSAIDs may worsen heart failure and cause 
unplanned healthcare (60).
Similar as for renal PIMs, there is no universally applicable list of DDSIs. Most 
PIP criteria do not include DDSIs as a specific category but have incorporated 
them in the overall list of PIMs (37). In Sweden, clinicians consult the Swedish 
medical products list (61) when they screen for DDSIs. 
2.5 Prevalence of potentially inappropriate prescribing
The prevalence of PIP has been assessed in numerous settings, populations and 
countries. Every second hospitalized older patient (62), home care patient (63) 
and nursing home resident (64) may be exposed to PIP. 
As the majority of prescribing to older patients happens in primary care (figure 2), it 
seems crucial to analyze the prevalence of PIP in an outpatient setting. Two system-
atic reviews conclude that approximately 20% of older community-living patients 
are exposed to PIP (65, 66). Drug groups commonly associated with preventable 
unplanned hospital admissions are antiplatelets, NSAIDs, diuretics (67), hypo-
glycaemic agents and central nervous system agents (68). Diagnoses that may evoke 
drug-related morbidity are for example hypotension, bleeding, heart failure, renal 
failure and electrolyte disturbances (68) (69). Of note, every second drug-related 
hospital admission may be preventable (70) (71). 
Single-study prevalence rates of PIP in the outpatient setting vary considerably 
between 17 % (72) and 94% (73). There are two explanations for these hetero-
genous results. 
First, the definition of PIP differs substantially between studies. The majority of 
studies use explicit Beers (26, 29, 30) or STOPP/START criteria (37), whereas few 
studies use implicit MAI criteria (40). The prevalence of PIP tends to be higher 
when using implicit compared to explicit criteria (>90% vs. 20%) (65). Some 
studies only assess one category of PIP, as for example DDSIs (74) or renal PIMs 
(50). Another observation is that the majority of studies focus on misprescribing 
or overprescribing, whereas underprescribing is only rarely taken into account. 
This is partly explained by the lack of clinical data in many studies. 
9Second, different data sources are used such as medical records, insurance data, 
prescription databases or administrative healthcare databases. An important advan-
tage of medical records data is that clinical and laboratory information is available. 
Many PIMs need clinical data for proper assessment. On the other hand, only small 
samples of patients may be analyzed which hampers generalizability. Advantages 
of the use of databases are the relative ease of data collection and the possibility 
to analyze large populations without selection or recall bias. Furthermore, such 
data can easily be reproduced and may serve as a valuable source for feedback on 
prescribing, as recently shown in a Scottish study in primary care (75). However, 
an important disadvantage of register data is that mainly explicit criteria may be 
analysed.
There have been conflicting results regarding the trend of the overall prevalence 
of PIP in older patients during the last two decades. According to a systematic 
review (65), it has remained stable around 20% which is somewhat surprising 
in view of numerous attempts to reduce PIP in older patients (76). Other studies 
suggest slight decreases (10) or increases (77, 78).
2.5.1 Prevalence of potentially inappropriate prescribing in 
 relation to renal function
According to a recent systematic review (79), there are twelve studies on the 
prevalence of renal PIP in older community-dwelling residents with impaired renal 
function (79). Participants were in mean between 71 and 85 years old. Different 
definitions of renal PIP were applied, and the formula used to calculate eGFR 
varied. These differences in study design explain that the observed prevalences 
varied between 1% to 37%.
2.5.2 Prevalence of drug-disease interactions
Little is known on the prevalence of drug-disease interactions in older patients. We 
are aware of one systematic review from 2013 including eight studies (80) together 
with five studies published since 2013 (81-85). The heterogeneity of definitions of 
DDSIs as well as different settings are major explanations for the range in preva-
lence of 3% (86) to 50% (82). Nursing home residents are more often exposed to 
DDSIs (50% (82)) than community-dwelling older patients (15-20%) (81, 83). 
2.6 Who is at risk for adverse drug reactions?
In order to target interventions aiming to reduce preventable drug-related mor-
bidity in older patients, it is important to identify risk factors for PIP and adverse 
drug reactions. 
10
PIP is associated with polypharmacy (65, 87). Parallel with the number of drugs 
the likelihood of PIP (65) and in particular drug-drug interactions increases (9, 88). 
Data regarding the association of sex, age and burden of comorbidity on the one 
hand and PIP on the other hand are conflicting (65). Examples for practice char-
acteristics that are associated with PIP are male sex of the prescriber (89) and 
localisation in an urbanized area (90).
Observational studies in older adults visiting the emergency department for drug-
related morbidity have shown that patients at risk are older, to a larger extent 
female (69), nursing home residents (91), have impaired renal function (92), are 
treated with more than five drugs (69) with prescriptions by multiple specialists 
(93), have recently started a new high-risk drug (69), or are treated with a PIP 
according to STOPP/START criteria (43). 
2.7 How to address potentially inappropriate prescribing
2.7.1 Potentially inappropriate prescribing – general practitioners’ 
perspective
GPs experience that single disease guidelines induce PIP (45, 94-96) because 
most of their older patients are multimorbid (6). GPs have to compromise between 
evidence-based and patient-centered care and may feel pressure from patients to 
prescribe, or pressure to please the patient (97). Furthermore, they may maintain 
PIP because they are aware of less-than-ideal care situations, such as the home-
dwelling patient with mild dementia who has an indication for insulin treatment 
but refuses help of home care nurses (97). The communication between primary 
and secondary care are suboptimal making it difficult to question indications for 
drug treatment (96, 98, 99). Of note, GPs do not agree on their responsibility for 
the entire drug list and may not want to question drug prescriptions released by 
other specialists (24). 
During the process of deprescribing, GPs evaluate risk and benefit of a drug treat-
ment and take into account the patient’s quality of life and life expectancy (100). 
However, GPs may have negative experiences in relation to deprescribing, espe-
cially when coming to e.g. hypnotics and sedatives (101). Thus, they may rather 
maintain the status quo of drug treatment than deprescribe (102). 
GPs question the utility of criteria to measure PIP as these often do not take into 
account the complexity of prescribing (103). Furthermore, they experience that 
PIP criteria as for example STOPP/START criteria are not applicable in primary 
care, as they are too vast and time-consuming (45, 101). At the same time, GPs 
demand simple measures to reduce PIP (45).
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2.7.2 Interventions to improve potentially inappropriate 
prescribing
In view of the gap between theoretical knowledge and its actual application by 
healthcare professionals (104) it is an interesting and highly relevant question 
what is likely to bring about change in clinical practice. This is what implementa-
tion research is about: “to understand what, why, and how interventions work in 
“real world” settings and to test approaches to improve them” (cited from (105)). 
Such interventions may be categorized into professional-oriented, organizational, 
financial or regulatory ones (106). Examples of professional and organizational 
interventions in the context of PIP in older patients are summarized in table 2. Of 
note, financial incentives and regulatory interventions are mainly used in com-
bination with professional-oriented or organizational interventions. Financial 
incentives are a powerful tool to improve clinical performance, but changes tend 
to cease when the incentive is removed (107). Neither financial nor regulatory 
interventions increase understanding. 
An important characteristic of professional-oriented interventions such as medica-
tion reviews is that the entire drug list is evaluated for PIMs, whereas organiza-
tional interventions rather focus on a limited number of severe and frequent PIMs. 
A systematic review identified 31 studies that analyzed the effectiveness of medi-
cation reviews as an isolated short-term intervention (109). In 26 out of 31 studies 
pharmacists performed the medication review and either gave prescribing recom-
mendations to physicians, or acted as part of a multidisciplinary team (109). The 
physician finally decided if and in what way drug treatment should be modified.
Only two out of 31 studies (109) dealt with physician-led medication reviews 
with the physician not being the researcher himself (117, 118). The way in which 
medication reviews were performed differed substantially between studies or was 
not sufficiently described. Four studies performing medication reviews based on 
STOPP/START criteria found a reduction of falls, delirium episodes, healthcare 
visits and length of hospital stay (42). However, according to two systematic 
reviews the clinical utility of medication reviews must be questioned despite 
slight improvements in prescribing and clinical outcomes shown in some single 
studies (108, 109).
Since 2012, physicians in Stockholm County have been required to perform and 
register medication reviews in older patients on a regular basis (see chapter 4.3.1). 
Collaboration with other healthcare professionals such as nurses, other special-
ists or pharmacists has been encouraged. The effects of such medication reviews 
on the  quality of prescribing and patient-related outcomes have not been studied, 
and there is limited knowledge on how healthcare professionals in primary care 
in Stockholm experience the work with medication reviews.
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Table 2. Examples of interventions that have been used to improve prescribing in 
older patients
Intervention Who intervenes What is done and how Studies or systematic 
reviews describing 
intervention
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Medication 
review
pharmacist alone 
or as part of a 
multidisciplinary 
team
pharmacist reviews 
medications and gives 
recommendations to 
physician who decides 
if changes in drug treat-
ment are performed
Christensen 2016 (108) 
Huiskes 2017 (109)
physician physician reviews medi-
cations and changes 
drug treatment
Gallagher 2011 (41)
Good 
Palliative-
Geriatric 
Practice 
algorithm 
physician physician reviews medi-
cation and focuses on 
indication and effective-
ness of drug treatment, 
possible adverse effects 
and dosing
Campins 2017 (110) 
Garfinkel 2010 (95)
Computerized 
support 
systems
physician computer applications 
that help clinicians 
to make therapeutic 
 decisions, for example  
recommendations on 
drug dosing in patients 
with impaired renal 
 function (111) 
Grol 2003 (112) 
Bryan 2008 (113)
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1
Academic 
detailing/ 
educational 
outreach 
visits
tutors and health-
care professionals
tutor visits healthcare 
professionals at their 
working place and pro-
vides information on how 
to change practice, for 
example how prescribing 
may be improved
O´Brien 2008 (114) 
Grol 2003 (112)
Feedback on 
performance
tutors and health-
care professionals
healthcare professionals 
are provided feedback 
on how they performed, 
for example their quality 
of prescribing
Ivers 2012 (115)
Reminders healthcare 
professionals
healthcare profession-
als are provided docu-
ments that remind them 
of an intended change 
in practice
May 2015 (116)
Local 
 consensus 
processes, 
interactive 
meetings
group of health-
care professionals 
with/without tutor
healthcare professionals 
agree on the necessity 
of a change of practice 
and on the way in which 
changes should be done
May 2015 (116) 
Grol 2003 (112)
1 Cited from (106)
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Medication reviews aim to achieve “pharmacological appropriateness”. In view 
of the complexity of PIP this implies a heavy workload which may be not be 
justified as one third of drug-related problems in older patients in primary care 
may be due to only three problems: 1) the absence of an indication for drug treat-
ment; 2) a lack of effectiveness of drug treatment and 3) long-term drug treatment 
instead of short-term (73) (119). Garfinkel et al. recommend the use of the “Good 
Palliative-Geriatric Practice algorithm” (table 2). This algorithm may be consid-
ered as a “reduced version” of a medication review. It focuses on the evaluation 
of the indication of drug treatment when taking into account the patient’s age, 
comorbidity and possible adverse drug reactions (95). Consequently, on average 
4.4 drugs per patient could be stopped, quality of life increased, and dementia 
symptoms improved (95, 120). Obviously, making sure that a drug has an indica-
tion and is effective seem to be the two most important steps during a medication 
review and may reduce a large proportion of all PIP. This corresponds well to the 
author’s clinical experience from the work with older patients. For example, drug-
drug interactions are closely linked to the number of drugs which implies that the 
prescriber takes care of them per se when removing drugs without indication (88). 
Computerized decision support systems that are linked to the electronic patient 
journal and alert physicians during the ordination process may enhance appropri-
ate prescribing (table 2). This is particularly true for the hospital setting whereas 
effects are less certain in the outpatient or primary care setting (113). A common 
complaint from prescribers is that they are overrun by alerts (121).
Several educational strategies have successfully improved prescribing (see even 
chapter 2.7.3). Educational outreach visits have small but potentially important 
effects on prescribing (114) (122), and feedback on performance may effectively 
change clinical practice (123) (115). Moreover, it is effective to remind healthcare 
professionals of an intended action (“reminders”) (123). Interprofessional discus-
sion may enhance agreement on the necessity of a change of practice and on the 
manner in which changes should be done (“local consensus process”). The com-
bination of several evidence-based strategies increases effectiveness. 
Several attempts have also been made to identify patients at risk for drug-related 
morbidity by means of regression models (124-126). This led to the development 
of screening tools forecasting adverse drug reactions similar to the Framingham 
risk score predicting the risk for cardiovascular mortality in patients with cardio-
vascular disease (127). For example, the GerontoNet ADR risk prediction tool 
(126) includes six risk factors: 1) ≥ four chronic conditions, 2) heart failure, 
3) liver disease, 4) renal impairment, 5) number of drugs, and 6) a history of ADR. 
However, these tools have not been implemented and tested prospectively (124). 
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2.7.3 Where and how are interventions aiming to improve 
potentially inappropriate prescribing conducted?
Research in this field increases which is illustrated by the growing number of 
 studies included in three systematic Cochrane reviews on this topic (original 
review from 2012 and two updates from 2014 and 2018 (76, 106, 128) (figure 3).
2012
•10 studies
•Seng
•5 hospital
•3 nursing homes
•2 primary care
•Intervenon
•9 complex, 
mul-faceted
intervenons of
pharmaceucal
care
2014
•12 studies
•Seng
•7 hospital
•3 nursing homes
•2 primary care
•Intervenon
•11 complex, 
mul-faceted
intervenons of
pharmaceucal
care
2018
•32 studies
•Seng
•16 hospital
•6 nursing homes
•10 primary care
•Intervenon
•31 complex, 
mul-faceted
intervenons of
pharmaceucal
care
Figure 3. Original Cochrane review (2012 (128)) and two updates (2014 (76), 2018 (106)) 
that describe interventions aiming to enhance appropriate prescribing in older patients.
Most studies were conducted in an inpatient setting. However, the number of  studies 
performed in primary care increased considerably from two in 2014 to ten in 2018. 
Moreover, the most recent review from 2018 identified 27 ongoing studies. The 
large majority of interventions are multifaceted and include medication reviews, 
educational interventions and financial incentives. The most important finding is 
that clinically relevant outcomes do not improve. 
2.7.4 Multifaceted educational interventions in primary care
According to the most recent Cochrane review on interventions to improve PIP 
in older patients (106) (figure 3), ten studies were conducted in primary care 
 settings with a total of 14 969 participants. Of these, only one used a multifaceted 
educational approach (129). Four other important studies (75, 130-132) have not 
been captured by the inclusion criteria of the Cochrane review (106) as they did 
not use validated PIP criteria (such as for example STOPP-START (37)). Table 3 
summarizes the methods and findings from these five studies.
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Table 3. Methods and results of five cluster-randomized studies on PIP in a  primary 
care setting using multifaceted educational approaches. The descriptions of the 
interventions are in part quoted from the original articles.
Avery 2012 (131), UK
Definition of PIP 3 PIMs: NSAIDs without proton-pump inhibitor, beta blockers and 
asthma, angiotensin converting enzyme inhibitor or loop diuretics 
without assessment of urea and electrolytes
Unit of allocation Practice/patient
Follow-up 6 months
Participants 72 general practices with a combined list size of 480 942 patients
Intervention Pharmacist-led, information technology-based intervention com-
posed of feedback, educational outreach, and dedicated support
Controls Simple computerized feedback + brief written educational  material
Endpoints Primary: % of patients at 6 months with at least one of three PIMs
Effects Odds Ratios in favour of intervention patients (CI 95%):
1) NSAIDs 0.58 (0.58-0.91)
2) betablockers 0.73 (0.58-0.91)
3) angiotensin converting enzyme inhibitor/loop diuretics 
0.51 (0.34-0.78)
Clyne 2015 (129), Ireland
Definition of PIP 34 PIMs, for example “NSAID (>3 months) for relief of mild joint 
pain in osteoarthritis”
Unit of allocation/analysis Practice/patient
Follow-up After 4-6 months assessment of outcomes (depending on when the 
practice had performed medication reviews in 50 randomly selected 
patients)
Participants 21 GPs and 196 patients
Intervention Pharmacist-led educational outreach visit on how to perform a medi-
cation review with a web-based pharmaceutical treatment algorithm
Controls Usual care and one-time simple patient-level feedback on PIP
Endpoints Primary: 1) % of patients with PIP and 2) mean number of PIMs in 
all intervention patients vs. all control patients group;
Several secondary endpoints
Effects Intervention patients ↓ odds (adjusted odds ratio = 0.32; 95% CI, 
0.15-0.70) of having PIP; mean number of PIMs in intervention 
patients 0.70 vs. 1.18 in control patients
Of note, the reduction in PIP was to a large extent due to the 
 reduction of one indicator (Proton pump inhibitor at maximum 
 therapeutic dosage for >8 weeks)
16
Dreischulte 2016 (75), Scotland
Definition of PIP 9 PIMs: for example NSAIDs, antiplatelets, oral  anticoagulant 
 without gastroprotective drug, and 3 clinical outcomes: 
 gastrointestinal bleeding, renal failure, heart failure 
Unit of allocation/analysis Practice/patient
Follow-up 48 weeks intervention + 48 weeks follow-up
Participants 34 primary care practices with 33 334 patients at risk (pre-intervention 
period) 33 060 patients at risk (intervention period)
Intervention Complex intervention combining professional education, informatics, 
and financial incentives
Controls Each practice was its own control due to stepped-wedge design
Endpoints Primary: rate of patients with high-risk prescribing 
Secondary: rate of hospital admissions per 10 000 person-years for 
GI ulcer/bleeding, heart failure or acute kidney injury
Effects Primary: ↓ from 3.7% to 2.2%
Secondary: ↓ from 55.7 to 37.0 (gastrointestinal bleeding)
↓ from 707.7 to 513.5 (heart failure)
not significant (renal failure)
Pit 2007 (117), Australia
Definition of PIP 3 PIMs: NSAIDs, low-dose thiazide diuretics as first-line therapy 
for hypertension, and benzodiazepines
Unit of allocation/analysis Practice/patient
Follow-up 4 and 12 months
Participants 22 GPs from 17 practices recruited 849 patients ≥ 65 presenting 
at practice during study period
Intervention Education (academic detailing, prescribing information and feed-
back), financial incentives, medication risk assessment, and 
 completion of a medication review checklist
Controls Control doctors received no intervention except for completing a 
clinical audit to encourage participation in the study, which included 
feedback on the number of medication reviews and medication 
risk factors
Endpoints Primary: number of patients with one of six possible outcomes 
(-2, -1, 0, 1, 2, 3) of an ordinal composite outcome measure of PIP; 
Secondary: ordinal outcome measures for each of the targeted 
drugs (neutral score (0), success (+1) (ie, recommendation was 
 followed), or failure (–1) (ie, recommendation was not followed)
Effects Intervention patients vs. control patients:
1) ↑ odds of having an improved composite score than patients in 
control group (Odds Ratio 1.86; 95% CI, 1.21–2.85) at 4 months, 
but not at 12 months
2) ↓ odds of using NSAIDs at 4 months, but not at 12 months
No significant changes regarding benzodiazepines or thiazide 
 diuretics at 4/12 months
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Rognstad 2013 (133), Norway
Definition of PIP 13 PIMs in patients aged ≥70 years
Unit of allocation/analysis Peer continuing medical education groups with GPs/group of 
patients that were prescribed PIMs by specific GP
Follow-up One year
Participants 449 GPs that were part of (pre-existing) peer continuing medical 
education groups who issued PIMs to 81 810 patients aged ≥70 
years before and 80 521 patients after educational intervention
Intervention Educational intervention composed of educational outreach visits, 
feedback, group discussion
Controls Control group: usual care (remark: peer continuing medical education 
groups received a similar educational intervention but on the topic 
of prescribing practice for respiratory tract infections (134))
Endpoints number of PIMs/100 patients issued by specific GP during pre-
intervention period (year 2005) compared to post-intervention 
period (July 2006-june 2007)
Effects  ↓10.3% PIMs/100 patients 
CI confidence interval; GP general practitioner; PIMs/PIP potentially inappropriate medicines/
prescribing.
The studies have several similarities. They all define specific subsets of PIMs, 
thus providing a very clear message to the prescribers. The interventions were 
very specific: drug treatment should be initiated or stopped, and the effects of 
changes in drug treatment may be observed within a few weeks. In all studies, 
clusters are randomised (practices or continuing medical education groups), but 
outcomes were assessed at patient level. Finally, all studies applied a combina-
tion of evidence-based educational strategies such as feedback on prescribing, 
educational outreach, reminders or group discussions.
The most distinct effect on clinical outcomes was achieved by Dreischulte et al. (75). 
The limited number of PIMs and the regular (every 8th week) feedback to pres cribing 
GPs are important explanations for the decrease in drug-related hospital admissions. 
Two studies (75, 131) had a “pragmatic” in contrast to an “explanatory” design (105, 
135). Key characteristics of pragmatic trials are that they evaluate the “effective ness 
of an intervention in a normal practice setting with the full range of study partici-
pants” (cited from (105)). Moreover, the intervention may be used in a flexible way 
as it would be in daily practice. Pragmatic trials may be considered as more “ honest” 
than explanatory trials, as they are conducted within a “daily work” setting. 
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2.8 Process evaluation of complex trials
The design and analysis of complex trials such as the multifaceted interventions 
presented in table 3 are a challenge because the intervention is applied at cluster 
level whereas the outcomes (at least partly) are assessed at patient level. The follow-
ing example may illustrate this challenge: An educational intervention is provided 
to primary care practices, and participating healthcare professionals are asked to 
review their patients’ medicines according to a new method. In this context it is 
essential to measure not only if prescribing improves, but also to understand who 
participates in the educational sessions, who uses the new method and how, and 
if the new method is still used several months after the intervention, to give only 
some examples. A structured framework such as the one proposed by Grant et al. 
(136, 137) facilitates the planning and reporting of such a trial (138). 
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3 AIM AND RESEARCH QUESTIONS
3.1 Overall aims
1) To increase knowledge on how commonly older patients attending primary 
care use potentially inappropriate medicines in relation to their renal function, 
and how frequently they are exposed to drug-disease interactions. 
2) To evaluate if an intervention on medication reviews combining several 
evidence-based educational strategies is a valuable measure to address 
 potentially inappropriate prescribing in primary care, and
3) To understand GPs’ and nurses’ views on potentially inappropriate prescribing 
and medication reviews.
3.2 Contents of thesis
Figure 4 illustrates the contents of this thesis based on three published articles 
and one manuscript. 
Research quesons Study design and data source
How
common?
What is the prevalence of 
I. PIP in relaon to renal funcon
II. drug-disease interacons
in older paents aending primary care?
I. + II. Cross-seconal populaon-based studies
using register data on diagnoses, drugs, 
healthcare consumpon, and creanine
How to 
address?
III. Does a mulfaceted educaonal intervenon 
given to GPs and nurses in primary care reduce PIP
and unplanned hospital admissions?
III. Pragmac cluster-randomised controlled trial
using regional healthcare administrave data for 
outcome assessment
How to 
understand?
IV. What are GPs’ and nurses’ views on PIP and 
medicaon reviews?
IV. Qualitave study
analysing diaries from educang pharmacists
with themac analysis
Figure 4. Contents of thesis. 
GP general practitioner, PIP potentially inappropriate prescribing.
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3.3 Research questions
1) How common is potentially inappropriate precribing?
a. What is the prevalence of drugs that are contraindicated in relation to 
renal function in older patients who attend primary care and have chronic 
kidney disease stage 3 or 4? (I)
b. What is the prevalence of excessive dosing in relation to renal function in 
older patients who attend primary care and have chronic kidney disease 
stage 3 or 4? (I)
c. What is the prevalence of drug-disease interactions in older patients who 
attend primary care? (II)
2) How to address potentially inappropriate prescribing?
a. Does a multifaceted educational intervention given to GPs and nurses in 
primary care 
i. reduce potentially inappropriate prescribing and unplanned hospital 
admissions? (III)
ii. increase the number of medication reviews? (III)
b. What are GPs’ and nurses’ views on potentially inappropriate prescribing 
and medication reviews? (IV) 
c. Why did prescribing not improve after a multifaceted educational 
intervention in primary care? (IV)
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4 RESEARCH METHODS AND MATERIAL
4.1 How common is potentially inappropriate prescribing?
4.1.1 Study design 
The percentage of older patients currently exposed to PIP in relation to renal function 
(I) or drug-disease interactions (II) was assessed in two descriptive cross-sectional 
studies. The study period was one year (figure 5). In study I, the study period started 
at different dates for each participant depending on the date of creatinine assess-
ment (index date) (figure 5), whereas the study period in study II was the same for 
all individuals (year 2016). One explanation for this long period is that an “average 
older patient” in the study population uses many drugs simultaneously (= poly-
pharmacy), but drug dispense may happen at several time points during one year. 
Another explanation specific to study I was that drug doses were to be calculated 
based on the number of purchased drug packages during one year. 
INDEX DATE
= date of first creanine assessment in individuals with at least one creanine in 2010
All drug purchase (n= 4 944 372 dispensings) during 1 
year aer index date, latest december 31, 2011
Morbidity
Figure 5. Illustration of time frames under which renal function, drug use and  morbidity 
were assessed in study I.
4.1.2 Study population
The prevalence of PIP in relation to renal function (I) was analysed in patients 
aged ≥65 years who attended primary care at least once year 2010, with at least one 
creatinine assessment in 2010, and who had an eGFR of 30–59 mL/min (CKD stage 
3) or 15–29 mL/min (CKD stage 4).
The prevalence of drug-disease interactions (II) was analysed in patients aged ≥65 
years who were registered with a primary care practice in Stockholm County in 
December 2015.
People who died or moved in and out of Stockholm County were excluded.
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4.1.3 Study I: Definition of potentially inappropriate prescribing 
in relation to renal function
In 2010, Stockholm County Council decided to integrate a computerized decision 
support system on drug prescription in impaired renal function in the electronic 
medical record (59). PIP in relation to renal function was defined with reference 
to the knowledgebase “Janusmed Drugs and Renal function” (version 2016). 
Janusmed is the Swedish adaptation of Finnish Renbase®, a comprehensive 
knowledgebase with evidence-based recommendations on drug use in patients with 
renal impairment. Renbase® refers to internationally accepted categories of CKD 
(139) and includes for every substance (a) a classification for each kidney function 
level (A: no need of dose modification. B: The information is not available or the 
recommendation is estimated based on the pharmacokinetic characteristics of the 
substance. C: Modification of the dose or dosage interval is needed. D: Use of 
the substance should be avoided.); (b) a short recommendation that may refer to 
dosing, but may also be a text suggesting to read the additional information; and 
(c) the additional information with the real recommendation in text. We analysed 
substances that should be dose-adapted (”C-substances”) and substances that are 
contraindicated (“D-substances”). C-substances were potentially inappropriate 
if 1) they were prescribed in a chronic manner. 2) their mean volume dispensed 
(Defined Daily Dose)/day exceeded the recommended dose. D-substances were 
considered as potentially inappropriate if dispensed at least once during the index 
year. For details, see methods section in paper I.
In 2011, physicians in primary care in Stockholm prescribed a total of nearly 700 
different substances (ATC 5th level) to patients aged ≥ 65. In order to delimit our 
analyses to a manageable amount of substances we applied the concept of “drug 
utilization 99%” (DU99) (140). This implied that we described the prevalence of 
PIP in relation to renal function within 99% of the total volume of all dispensed 
prescriptions measured as Defined Daily Doses in patients with CKD stage 3 or 4. 
We adapted Janusmed for the purposes of study I according to figure 2 in the 
published paper (I), and analysed the prevalence of 45 C- and 5 D-substances in 
patients with CKD stage 3, as well as 41 C- and 25 D-substances in patients with 
CKD stage 4.
4.1.4 Study II: Definition of drug-disease interactions
Drug-disease interactions were chosen with reference to STOPP/START Criteria 
version 2 (37). As these criteria do not include a specific list of drug-disease inter-
actions, we decided for each of the 80 STOPP-indicators if it is a drug-disease 
interaction according to the definition provided by Pugh et al. (48): “drugs that 
worsen a pre-existing condition”. Details on the selection process are shown in 
appendix of manuscript II. Finally, 33 drug-disease interactions were assessed for 
their prevalence. 
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4.2 Data sources
Sweden holds many registers that can be used for research purposes (141). The 
Swedish personal identity number (142) allows to link information from different 
registers and thus to create a complete “painting” of a patient taking into account 
sex, age, morbidity, drug use, healthcare consumption and laboratory data (figure 6).
Laboratory data
- creanine
Prescribed Drug
Register
- dispensed drugs
- drug doses
- prescriber
Regional 
healthcare
databases
- sex and age
- death
-healthcare consumpon
- primary care
diagnoses
Naonal Paent 
Register
- inpaent diagnoses
Personal 
identy
number
Figure 6. Illustration of registers and data that were linked using the personal identity 
number. Laboratory data were linked in study I only.
We linked information from:
1) Stockholm County’s regional healthcare databases (Stockholm regional 
healthcare data Warehouse (25), Vårdanalysdatabasen VAL). It contains all 
consultations in primary and secondary care as well as hospital admissions. 
Information on at least one diagnosis is available for more than 95% of 
primary care consultations.
2) The National Patient Register. Information on at least one diagnosis is 
 available for 99% of outpatient specialist consultations, and for 99% of 
inpatient hospital admissions. With some exceptions (for example, cancer 
diagnoses), diagnoses in the national inpatient register have a positive 
predictive value of 85% to 95% (143).
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3) The Prescribed Drug Register (144). It contains data on all prescription drugs 
dispensed in Sweden from July 2005 and later, their amounts and  dosages, 
as well as prescriber information. The information has a high  validity. Of 
note, neither in-hospital nor over-the-counter drugs are included.
4) For study I, data from the Stockholm CREAtinine Measurements (SCREAM) 
database were retrieved (145). In addition to the registers described above 
SCREAM contains laboratory data from one of the three laboratories (Aleris, 
Unilabs or Karolinska University Laboratory) performing the majority of 
medical analyses in Stockholm County. 
 The estimated glomerular filtration rate was calculated with CKD-EPI 
formula based on creatinine values assessed during year 2010 (146). EGFR 
was categorized into (139): CKD stage 1 or 2: eGFR ≥ 60 mL/min; CKD 
stage 3: eGFR 30–59 mL/min; CKD stage 4: eGFR 15–29 mL/min; CKD 
stage 5: eGFR < 15 mL/min.
4.2.1 Statistical considerations
I: The prevalence of PIP in relation to renal function was stratified by CKD 
stage 3 and 4. We calculated two-tailed 95% binomial confidence intervals for 
prevalences. We calculated the proportion of patients with potentially excessive 
doses as “number of patients with potentially excessive dose of specific substance/
number of patients with specific substance”. Data were extracted from SCREAM 
(145, 147) with R (https://www.r-project.org). Statistical analyses were undertaken 
with STATA version 14. 
II: Three analyses were performed: 1) Prevalence of DDSIs in the entire study 
population; 2) Prevalence of the interacting drug in patients with interacting disease; 
and 3) Prevalence differences in two patient groups who all had a pain diagnosis: 
The prevalence of NSAIDs in patients with interacting disease was compared to 
the prevalence of NSAIDs in patients without interacting disease. Prevalence dif-
ferences and two-tailed 95% confidence intervals were calculated. Data extraction 
was performed with SAS Enterprise Guide version 7.1, and statistical analyses 
were undertaken in STATA version 14.
4.3 How to address potentially inappropriate prescribing 
in clinical practice?
4.3.1 Study design and study population (III)
We designed a pragmatic cluster-randomised trial in primary care in Stockholm. The 
intervention was multifaceted and comprised several evidence-based educational 
strategies. The study period was originally planned to 12 months, but had to be 
shortened to 9 months (1st of January to 30th of September 2013) due to the finan-
cial incentives tied to basic medication reviews (see paper III, box 1 for details). 
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The clusters were primary care practices, and the individuals were patients aged 
≥65 registered with the participating primary care practices. The multifaceted 
 educational intervention should help GPs and nurses to develop a working proce-
dure on medication reviews, and GPs and nurses were asked to perform medica-
tion reviews in their older patients. 
As mentioned in chapter 2.8, the design, interpretation and reporting of multi-
faceted interventions with cluster-randomisation is complex because the interven-
tion is applied at a cluster level whereas the outcomes (at least partly) are assessed 
at individual level. Therefore, the methods of study III are reported following 
the framework on process evaluations proposed by Grant et al. (137). Figure 7 
illustrates the domains proposed in the framework, the corresponding framework 
questions, and which kind of collected data may serve as a source to answer the 
framework question.
Of note, we used the framework during the reporting but not the planning phase. 
When planning the trial, we used our “common sense” to decide which type of 
data material to collect at which time point. This allowed use to generate but not 
to test hypotheses (137). The time constraints we faced were the major reason 
for not using a framework in the planning phase already. The trial had to be pre-
pared within four months (May 2012: decision to perform trial; September 2012: 
recruitment of practices started). The short time frame also partly explains the 
weaknesses of the process evaluation.
Besides the framework domains and questions illustrated in figure 7, the frame-
work includes three more questions:
1) Are there unintended changes in processes and outcomes, both related to the 
trial intervention and unrelated care? We were not able to answer this question.
2) What theory has been used to develop the intervention?
 In collaboration with two experienced clinical pharmacists working for the 
committee we developed a multifaceted educational intervention (see paper 
III: figure 3 and appendix) that comprised:
a) A first educational outreach visit given to GPs and nurses at each practice 
with a powerpoint presentation including
i) theoretical knowledge on PIP according to the Swedish criteria (54)
ii) feedback on prescribing patterns on practice or county level:
(1) polypharmacy: number of patients aged ≥65 with 5-9 drugs or 
10 and more drugs registered with the practice
(2) “drugs to avoid”: use of longacting benzodiazepines, anti-
cholinergic drugs, tramadol and propiomazin among patients 
aged ≥65 registered with the practice
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(3) PIP in relation to renal function: top-10 PIMs in relation to renal 
function in Stockholm County, and information on the computer-
ized decision support system (“Janusmed”, see chapter 4.1.3) that 
is integrated in the electronic medical record
(4) drug-drug interactions: 4-7 most prevalent drug-drug interactions 
in older patients in Stockholm County, and information on the 
computerized decision support system for drug-drug interactions 
that is integrated in the electronic medical record (148)
(5) drug-disease interactions: overall presentation of the “START”-
section (“diagnose-specific” chapter) of the Swedish criteria (54) 
(see table 1), and presentation of the eleven diagnoses for which 
there are diagose-specific recommendations on interacting drugs.
iii) the development of a working procedure on medication reviews 
b) A second, reminding educational outreach visit three months after the 
first visit.
3) What is the wider context in which the trial is being conducted?
 The primary care system in Stockholm is described in paper III, box 1.
 Since the 1990’s, Stockholm County has built up a well-functioning 
organization promoting the rational use of medicines (149). The “Regional 
Drug and Therapeutics Committee” is part of this organization. It employs 
physicians and pharmacists who perform educational outreach visits in pri-
mary care in order to give feedback on prescribing patterns and to promote 
changes in prescribing. 
 In 2012, the Swedish legislation was updated, and Stockholm County issued 
new guidelines on the performance of medication reviews (see paper III, 
appendix). All levels of health care should perform medication reviews 
in older patients on a regular basis. The guidelines differentiated between 
“basic” and “comprehensive” medication reviews, and a financial incentive of 
300 SEK (≈32 €) was tied with the performance of basic medication reviews. 
Stakeholders in Stockholm County assigned the Regional Drug and Thera-
peutics Committee to spread the knowledge on the new guidelines on medica-
tion reviews in primary care. We got the possibility to randomize primary care 
practices and applied for ethical approval.
 In collaboration with two experienced clinical pharmacists working for the 
Regional Drug and Therapeutics committee (149) we designed a multifaceted 
educational intervention. The incentive was given independently of whether 
the practice was participating in the intervention or not or whether it had 
been randomized to intervention or control group.
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Figure 7. Illustration of the process evaluation for complex trials proposed 
by Grant et al. (137) in relation to study III.
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4.3.2 Data material
This chapter describes the following data material shown in figure 7: 1) the  working 
procedure on medication reviews created during the educational sessions; 2) the 
tutors’ diaries; 3) and how the participation in the educational sessions was docu-
mented. Further data material shown in figure 7 is not described in this thesis.
4.3.2.1 Working procedure
Based on the new guidelines on medication reviews (150), relevant literature (27) 
and clinical experience, we developed a working procedure on comprehensive 
medication reviews (figure 8). During the education session, GPs and nurses dis-
cussed the ”Who, How, When” of each step of a medication review. 
Figure 8. Suggested working procedure for medication reviews.
4.3.2.2 Tutors’ diaries written after both educational sessions (IV)
The tutors who performed the educational outreach visits had several years of 
experience with academic detailing in primary care [19]. The writing of diaries 
after each educational session was a standardised part of their work. The purpose 
of the diaries was to document and structure the pedagogical process of academic 
detailing. The tutors were not steered in their reporting and had the maximum 
freedom of writing whatever they considered to be important regarding their 
purpose. In the context of our trial, they had decided to do the same after every 
educational session. When the tutors presented their diaries for the research group, 
we discovered they contained unexpectedly rich and extensive data. As we were 
not aware of any study analysing GPs’ and nurses’ views on medication reviews 
according to the Swedish legislation (151), we decided to analyse the diaries by 
a qualitative approach and obtained ethical approval.
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We hoped to find a hint in the diaries regarding the question to why the trial did not 
improve prescribing. When the analysis progressed, the initial aim was modified 
into the final aim, which was to analyze GPs’ and nurses’ views on PIP and medi-
cation reviews in older patients in primary care.
4.3.2.3 Participation in educational sessions
The participating GPs and nurses signed the participation lists during the first and 
second educational sessions, and stated their profession. The “sums of partici-
pating physicians/nurses” were divided by the “number of employed physicians 
and nurses according to register data obtained prior to the study”. We analysed 
participation on a group level only and did not take into account if the same person 
participated both educational sessions.
4.3.3 Definition of potentially inappropriate prescribing (III)
Despite several disadvantages with the Swedish criteria (38, 54) (table 1) health-
care professionals in Stockholm County should refer to them when they perform 
medication reviews in older patients. We therefore assessed PIP in relation to 
five categories proposed in the “misprescribing” section (table 1) of the Swedish 
criteria version 2010 (54): polypharmacy, drugs to avoid, PIP in relation to renal 
function, drug-drug and drug-disease interactions. As the Swedish criteria do not 
contain a specific list of drug-drug and drug-disease interactions, we created a 
detailed list of potentially inappropriate interactions with reference to published 
literature (for details see paper III, appendix).
It is important to mention that we were not able to assess the Swedish criteria in 
their entirety, as we neither had access to clinical data nor written information 
from the electronic medical record. This implied that we could not measure 1) the 
indication for drug use (chapter 1.2 in Swedish criteria), 2) inappropriate drug 
regimen (chapter 1.3 in Swedish criteria), 3) inappropriate dosing (chapter 1.4 in 
Swedish criteria) and 4) PIP in relation to specific symptoms such as hypotension 
(chapter 1.8 in Swedish criteria).
4.3.4 Outcomes
The effects of the intervention were assessed at practice (number of registered 
medication reviews) as well as patient level.
The primary combined outcome was the number of patients with ≥ one unplanned 
healthcare consultation defined as “unplanned hospital admission and/or emergency 
department visit” assessed at patient level. A selection of important secondary 
outcomes are presented in figure 9.
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Primary outcome:
Unplanned hospital admission
and/or emergency department visit
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- PIP in relaon to renal funcon 
- drugs that should be avoided
- drug-disease interacons
Secondary outcomes:
- polypharmacy
- drug-drug interacons
educaonal
session 1
educaonal
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medicaon reviews
Study period (1 january to 30 september 2013)
Outcomes at 
paent level
Outcome at 
cluster level
Figure 9. Which outcomes were assessed in study III, and when? See paper III, 
 appendix, for details on the definition of PIP.
PIP: potentially inappropriate prescribing
4.3.5 Statistical considerations
Details on the calculation of the sample size are reported in the methods section 
in paper III.
The main post-intervention analysis assessed differences between patients aged 
≥65 in intervention and control group. Risk differences between binary outcomes 
at patient level were calculated using a generalized linear model with binomial 
distribution and identity link. The difference in rates of medication reviews/ 
registered patients were evaluated with a t-test. Supplementary analyses included 
a before-after analysis (difference-in-differences). This approach decomposes 
outcomes into a group effect (difference between intervention and control group), 
a period effect (difference between after and before the intervention, time trend), 
and an intervention effect (difference-in-differences) estimated as the period × 
group interaction. Results are reported with a 95% confidence interval (95% CI). 
For the patient-level outcomes, we took into account the clustering of patients 
within practices. All analyses were undertaken in Stata version 14.
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4.4 Ethical considerations
In papers I and III and in manuscript II, epidemiological data from different regis-
ters were analyzed. The personal identity number that is specific for each individual 
was replaced by a random number which implies that it was not possible to identify 
individuals. Furthermore, all analyses were performed at group level only. Both 
procedures protect the individual’s integrity. 
Differences in quality of health care in relation to caregivers, sex, age or socio-
economics may cause debate. Still, it is important to illuminate if such differences 
exist in order to improve the quality of health care.
Data for papers III and IV were collected during the cluster randomized controlled 
trial (paper III). This design was chosen because it permits to answer the research 
question in an efficient manner. The study was performed according to scientific 
recommendations on the performance of cluster randomized trials. All medical 
directors of participating primary care practices were informed about the aim 
of the study and that confidentiality was ensured. Participation in the trial was 
voluntary. The medical directors of the participating practices signed informed 
consent. Medication reviews are a part of routine health care offered by primary 
care. There was a risk that patients at control practices may have felt their rights to 
receive equal care curtailed, as GPs and nurses in control practices were educated 
>9 months later than GPs and nurses in intervention practices. Still, we considered 
the risks with randomization as minor and thus acceptable. All data from practices 
and registered patients were analyzed confidentially, and identifying information 
was not possible to anyone who was not directly involved in the study. 
Regarding paper IV, the tutors consented to the analysis of the diaries. As the GPs 
and nurses who attended the educational sessions were not aware that the diaries 
would be analysed we applied and obtained ethical approval to analyse them in 
addition to the earlier approval for study III (152). Moreover, GPs and nurses were 
anonymous to the researchers, and it was not possible to identify them based on 
the tutors’ diaries.
We considered that the benefits with this research project outweighed possible 
harms.
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5 RESULTS
5.1 How common is potentially inappropriate prescribing?
5.1.1 Prevalence of potentially inappropriate prescribing in 
 relation to renal function (I)
In 11% of older patients an eGFR ≤ 59 ml/min was observed (figure 10). Among 
these, 30 372 patients had CKD stage 3, and 2161 patients had CKD stage 4. 
Contraindicated medicines were used by 9 vs. 38% of patients with CKD stage 3 
vs. 4. Excessive dosing was present in 43% of patients with CKD stage 3, and in 
58% of patients with CKD stage 4. 
aged ≥65 in Stockholm County 2010
accessing primary care ≥ once 2010
creanine measurement ≥ once 2010/11
esmated glomerular
filtraon rate ≤ 59ml/min
chronic kidney disease stage 3
chronic kidney disease stage 4
Stage 3
Stage 4
307 000
30 372
2 161
Figure 10. Study population (yellow and blue) and prevalence of potentially inappropriate 
prescribing in relation to renal function.
In both CKD stage 3 and 4, NSAIDs and antidiabetics were the most frequently 
encountered contraindicated drug groups. The three most prevalent contraindicated 
drugs are shown in table 4.
Table 4. Most commonly dispensed contraindicated drugs in patients with 
impaired renal function
% of patients with CKD stage 3 (95% CI) 
n=30 372
% of patients with CKD stage 4 (95% CI) 
n=2 161
nitrofurantoin 4.9 (4.7 to 5.2) codeine 9.4 (8.2 to 10.8)
dextropropoxyphene 3.0 (2.9 to 3.2) diclofenac 7.0 (5.9 to 8.1)
methenamine 1.8 (1.7 to 2.0) dextropropoxyphene 4.8 (3.9 to 5.8)
CKD chronic kidney disease, CI confidence interval.
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Among the ten most commonly overdosed substances were drugs acting on RAAS 
(3 substances among top-10, in both CKD stage 3 and 4) and opioids (3  substances 
among top-10 CKD stage 3, 2 substances among top-10 in CKD stage 4) (figure 11). 
At the same time, drugs acting on RAAS were much more commonly overdosed 
than opioids (yellow-colored part of bar in figure 11). In patients with CKD stage 
4, simvastatin and zopiclone were commonly used and in more than 30% of cases 
excessively dosed.
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Figure 11. Graphical illustration of the ten most prevalent C-substances that were 
 correctly (green) or excessively (yellow) dosed in patients with impaired renal function. 
(CKD chronic kidney disease.)
We found that only a few C-substances accounted for the majority of excessive 
dosing, meaning that there was a long “tail” of C-substances used by less than 5% 
of the study population (figure 11 and also paper I, figures 4a and 4b).
5.1.2 Prevalence of drug-disease interactions (II)
Among 336 295 older patients registered in primary care in Stockholm, 10.8% had 
at least one DDSI. Most common was the use of NSAIDs in patients with hyper-
tension (figure 12). It explained more than 75% of the prevalence of all DDSIs. 
In total, NSAIDs were implicated in five out of a total of 31 DDSIs.
The most common interacting diseases were cardiovascular diseases, benign pro-
static hyperplasia, urinary incontinence and dementia. In particular patients with 
constipation were treated possibly inappropriately as half of them received a drug 
(mainly opioids) that may worsen their constipation. 
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Figure 12. Number of patients with an interacting drug (red) grouped by the prevalence of the 
interacting disease (red+blue). The percentages indicate the prevalence of the interacting drug 
among patients with the interacting disease. The numbers to the left relate to the legend.
1 NSAID, 2 COX-2 selective NSAID, 3 antimuscarinic drug, 4 anti-muscarinic  bronchodilator, 
5 tricyclic antidepressant, 6 neuroleptic, 7 NSAID, 8 thiazolidenedione, 9 loop diuretic, 10 antimus-
carinic drug, 11 antimuscarinic drug,12 tricyclic antidepressant, 13 oral bisphosphonate, 14 NSAID, 
15 thiazide diuretic, 16 oestrogen, 17 oestrogen,18 benzodiazepine,19  prochlorperazine or meto-
clopramide,20 antipsychotics, 21 low-dose acetyl salicylic acid without proton-pump-inhibitor, 
22 non-COX-2 selective NSAID without proton-pump-inhibitor  or H2-blocker, 23 high-dose 
acetyl salicylic acid without proton-pump-inhibitor, 24 opioid, 25 antimuscarinic/anticholinergic 
drug, 26 oral iron,  27 verapamil, 28 aluminium antacid, 29 anti-muscarinic bronchodilator,  
30 antimuscarinic drug, 31 tricyclic antidepressant
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15,1%
We compared the prevalence of NSAIDs in two patient groups all having a pain 
diagnosis: those with an interacting disease (such as heart failure) and those without 
(figure 13). 
We found that patients with an interacting disease less commonly use NSAIDs. 
For example, patients with heart failure had a 15% lower prevalence of NSAIDs 
than patients without heart failure.
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Figure 13. Prevalence differences and 95% confidence intervals of NSAIDs in patients 
with one or several pain diagnoses and with/without an interacting disease. 
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5.2 How to address potentially inappropriate prescribing?
5.2.1 Effects of multifaceted educational intervention (III)
In total, 69 practices were recruited corresponding to one third of all practices in 
Stockholm County. We randomized 34 practices to the intervention group. The 
tutors performed educational outreach visits in 33 intervention practices, as one 
practice dropped out. 
The primary outcome was observed in 22.8% of patients in intervention practices 
and 22.0% of control practices (non significant) (figure 14, data points year 2013 
in the right part of the graph). 
Patients in the intervention group had a higher prevalence of the primary outcome 
already during 2012, the year before the trial (figure 14, data points year 2012 in 
the left part of the graph). Still, even when performing a difference-in-differences 
analysis taking into account this imbalance we did not find a significant difference 
between intervention and control practices.
Moreover, we observed neither a significant difference in the rates of medication 
reviews (intervention vs. control 0.13 vs. 0.16) nor a decrease in PIP in the inter-
vention practices (table 5).
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Table 5. Effect of multifaceted intervention in 69 primary care practices (34 intervention 
and 35 control practices) on patient-level outcomes. Intervention effect measured with 
difference-in-differences analyses1. 
Risk difference in % (95% CI) in 34 
intervention vs. 35 control practices2
Primary outcome ≥1 unplanned hospital admission 
and/or emergency department visit 3
-0.1 (-0.7 to 0.4)
Secondary outcomes ≥1 unplanned hospital admission -0.5 (-0.96 to 0.03)
≥1 emergency department visit -0.2 (-0.7 to 0.4)
Number of deaths -0.08 (-0.28 to 0.12)
Minor polypharmacy4 0.06 (-0.01 to 0.12)
Major polypharmacy4 -0.1 (-0.5 to 0.3)
≥1 drug to avoid/anticholinergic 0.4 (-0.1 to 0.9)
≥1 drug-drug interaction -0.1 (-0.6 to 0.3)
≥1 drug-disease interaction 0.16 (-0.07 to 0.40)
1 The difference-in-differences approach decomposes outcomes into a group effect (difference between 
intervention and control group), a period effect (difference between after and before the intervention, time 
trend), and an intervention effect (difference-in-differences) estimated as the period × group interaction
2 Intention-to-treat-analysis: 34 randomized practices were analysed including one drop-out practice
3 Intracluster-correlation coefficient: 0.00464 (0.00273–0.00645)
4 Minor: 5-9 substances, major: ≥10 substances during April 1 – July 31, 2013
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Figure 14. Prevalence of the primary outcome (= at least one unplanned hospital 
admission or emergency department visit) year 2012 (left) and 2013 (right). 
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Among 33 intervention practices that completed the study, 74% of GPs (n=194) 
participated in the first educational session and 62% (n=189) in the second one. 
The corresponding percentages for nurses were 54 (n=113) and 46% (n=89), 
respectively. 
We observed that the working procedures on medication reviews which GPs and 
nurses filled out during the educational sessions differed substantially, as illustrated 
in figure 15. Some practices were able to define the “Who, How, When” of the 
different steps during a medication review (left part of figure 15), whereas other 
practices were not (right part of figure 15).
Figure 15. Examples of two working procedures on medication reviews developed by 
GPs and nurses in two intervention practices (see figure 8 for translation to English). 
5.2.2 GPs’ and nurses’ views on potentially inappropriate 
prescribing and medication reviews (IV)
We identified five themes: 1) Complexity in 3 ‘P’: patients, pharmacotherapy, and 
primary care; 2) What, when, who? Clash between GPs’ and nurses’ experiences 
and guidelines; 3) Real-world problems and less-than-ideal solutions; 4) Eureka? 
Experiences with different steps during a medication review; and 5) Threats to 
GP autonomy. 
We found several areas of accordance where GPs and nurses shared the same view 
(themes 1 and 5), but even areas of conflicting views (themes 2-4). 
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GPs and nurses agreed that the clinical evaluation of older patients and their drugs 
is complex (theme 1) (figure 16). Drug treatment was only one piece of the com-
plicated puzzle of medical care in older patients. To evaluate if an older patient’s 
symptom is due to the underlying disease or a side effect of drug treatment was 
also challenging. 
“These paents have several 
challenges beyond the 
complicated medical regimen.”
“With reference to screening for 
side effects with a standardized 
quesonnaire, one GP suggested 
that “all” elderly paents 
experience vergo”
Figure 16. Complexity of clinical evaluation of older patients. Example from theme 1.
GPs’ and nurses’ did not agree with the guidelines’ definition of medication reviews 
(theme 2) (figures 17 and 18). They expressed that medication reviews are a 
natural part of every consultation, and that they did them continuously and when 
required (figure 17). Furthermore, they shared views regarding the segmentation 
of medication reviews into ‘basic’ and ‘comprehensive’: this did not comply with 
their clinical experience (figure 18).
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According to the guidelines, medicaon 
reviews are a separate task which must be 
both documented and coded in the 
electronic paent record.
Though unspoken, there was a feeling that 
”we are doing this all the 
me… we have 
always done this,” at least in some people.
Medicaon reviews 
are a separate task
Medicaon reviews 
are part of every 
consultaon
Figure 17. Are medication reviews a separate task or part of every consultation? 
Example from theme 2.
According to guidelines basic and 
comprehensive reviews are different tasks
“A GP menoned that he incorporates a 
review of medicaons during every paent 
encounter, both basic and comprehensive 
reviews of medicaons, and that he had 
always done so. He menoned several 
mes that he was not able to see a 
difference between the two.”
basic medicaon review
≠ 
comprehensive
medicaon review
basic medicaon review
= 
comprehensive
medicaon review
Figure 18. How do basic and comprehensive medication reviews differ? Example from 
theme 2.
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6 DISCUSSION
6.1 Main findings 
Older patients with impaired renal function are commonly exposed to PIP in 
relation to renal function. Excessive dosing is more common than the use of 
contraindicated drugs (CKD stage 3: 43 vs 9%; CKD stage 4: 58 vs 38%). A few 
drug groups were overrepresented: drugs acting on the RAAS and opioids among 
excessively dosed drugs, and NSAIDs and antidiabetics among contraindicated 
drugs. Only a minority of excessive dosing is likely to cause severe adverse drug 
reactions, such as codeine.
Drug-disease interactions are less common than PIP in relation to renal function. 
At least one DDSI was observed 10.8% of older patients in primary care. The most 
common DDSI was NSAIDs/hypertension (8.1%). We found that NSAIDs were 
prescribed cautiously to patients with interacting diseases.
It is unclear how GPs and nurses in primary care should address PIP in older 
patients. The multifaceted educational intervention neither reduced PIP nor 
unplanned healthcare. Moreover, intervention practices did not perform more 
medication reviews compared to control practices. Major reasons for these results 
may have been “complexity” and “dilution”.
We understood more about GPs’ and nurses’ views on PIP and medication reviews. 
We found several areas of accordance where GPs and nurses expressed the same 
views, but even areas of conflicting views. GPs and nurses agreed on the complexity 
of the clinical evaluation of older patients, PIP and medication reviews. Both GPs 
and nurses expressed that guidelines clash with clinical practice in primary care. 
6.2 How do the main findings fit in?
6.2.1 Prevalence of potentially inappropriate prescribing
The observed prevalence of PIP in relation to renal function was higher than in for-
mer studies in community-living older adults (153, 154), whereas the prevalence of 
DDSIs was within the frame of prevalences found in former studies ranging from 
3% (86) to 50% (82). However, it does not seem reasonable to compare overall 
prevalences at all, as the differences between our and former studies as well as 
between former studies are too substantial. 
Regarding studies on renal PIP, these differences refer to the definition of PIP, the 
data sources used to assess the prevalence, the formula used to estimate eGFR, the 
categorization of eGFR, and the way drug doses were calculated. For example, 
Chang et al. (153) identified the most commonly prescribed drugs in the study 
population, chose 40 renal PIMs that should be dose-adapted with reference to a 
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consensus validation list from 2009 (155), calculated eGFR with the Modification 
of Diet in Renal Disease (146) equation, and categorized patients with impaired 
renal  function according to “30-49 ml/min” and “15-29 ml/min”. Instead, we 
evaluated 50 renal PIMs in patients with CKD stage 3 and 66 in patients with 
CKD stage 4, used CKD-EPI formula to calculate eGFR, and classified eGFR 
into “30-59ml/min” and “15-29 ml/min”. Erler et al. calculated drug doses with 
reference to the maximum drug dose, whereas we used the Defined Daily Dose 
(“the assumed  average maintenance dose per day for a drug used for its main 
indication in adults”, quoted from [18]) which implies a lower reference dose. 
We also observed substantial design differences in between studies on DDSIs. 
To our knowledge, the study by Lau et al. (85) is the only one besides ours that 
defines DDSIs with reference to STOPP version 2. Still, Lau et al. considered only 
25 STOPP indicators to be DDSIs whereas we concluded that 33 STOPP indica-
tors were DDSIs. Lau et al. did not include the interaction NSAIDs/hypertension 
whereas we did. Furthermore, the settings and methods of assessment differ: Lau 
et al. used clinical information from 182 patients discharged from hospital in 
Hongkong, whereas we used register data from community-living older patients 
registered with 206 primary care practices in Stockholm County.
Due to the differences in definitions of renal PIMs and DDSIs in our study com-
pared to former studies, even the specific substances figuring as PIMs differed. 
For example, Chang et al. defined renal PIMs with reference to a consensus list 
(155) that did not include drugs acting on RAAS, whereas we defined renal PIMs 
according to Janusmed that includes drugs acting on RAAS, and found that these 
were highly prevalent. Chang et al. reported moreover that ranitidine,  allopurinol 
and metformin were the most commonly overdosed substances. In our study, 
allopurinol and metformin were among the top-10 renal PIMs in CKD stage 3, 
and allopurinol among the top-ten in CKD stage 4. Regarding specific DDSIs, 
we found that the interaction between NSAIDs/hypertension was far more preva-
lent than all other DDSIs, whereas Lau et al. describe that DDSIs including anti-
cholinergic drugs were most prevalent; at the same time, Lau et al. did not assess 
NSAIDs/hypertension.
However, despite all these differences there is one common finding. In general, 
only a few substances account for the majority of PIP, and there is a long tail of renal 
PIMs and interacting drugs that are only rarely used. This finding is encouraging 
as it shows that the complexity of PIP may be reduced by focusing on the most 
common PIMs in the underlying population. This may in turn be used to create 
concise feedback on prescribing which was shown in a Scottish primary care 
study that used similar educational approaches as we did (75) (table 3). During 
the intervention, feedback on prescribing of a selection of clinically important 
PIMs that cause preventable drug-related morbidity was provided. Consequently, 
PIMs and unplanned hospital admissions decreased. In Norway, PIP improved 
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after feedback on prescribing given to GPs (130) (table 3). The study applied a 
colleague-to-colleague model and focused on 13 PIMs. The two most important 
explications for the favourable results in both studies are the concise definition 
of PIP and the repeated feedback. 
6.2.2 Physicians prescribe carefully, but there is room 
for improvement
We found that physicians prescribe cautiously to their older patients. 
The high prevalence of excessive dosing in patients with impaired renal func-
tion was mainly due to the prescription of drugs acting on RAAS. On the other 
hand, renal PIMs with a higher likelihood of causing severe harm such as opioids 
were only rarely overdosed. These findings are in line with former findings from 
outpatient populations (50, 154). Regarding the prescription of drugs acting on 
RAAS physicians are somewhat in an awkward position as patients with heart 
failure and renal impairment should receive ACE-inhibitors in high doses to treat 
heart failure but at the same time not because ACE-inhibitors in high doses may 
worsen renal function. Moreover, RAAS-active drugs are recommended as first 
line drugs in treating high blood pressure in patient with chronic kidney disease. 
A high prevalence of ACE-inhibitors in patients with renal impairment is thus not 
exceptionally “inappropriate”, as long as GPs follow up on renal function and 
electrolyte levels (which we did not to capture). Interestingly, ACE-inhibitors’ 
potential to induce a deterioration of renal function has been questioned (156). 
Likewise, we found evidence that physicians are aware of severe DDSIs such as an 
aggravation of heart failure due to NSAIDs: these drugs were only rarely prescribed 
to patients with heart failure. These findings of “cautious prescribing” may explain 
why physicians who participated in the educational sessions on medication reviews 
(study III) expressed: “We are doing this (=reviewing medicines) all the time, we 
have always done this” (IV, figure 17). It is important to further elucidate to what 
extent physicians prescribe cautiously or harmfully even in relation to other DDSIs.
However, there is room for improvement of prescribing. Excessive dosing of 
 opioids may cause substantial harm and is not acceptable even if only a few 
patients were exposed to it. It is neither acceptable that there were still 1920 older 
patients with heart failure who were dispensed NSAIDs at least once during 2016. 
Moreover, we may not have captured PIP in its wholeness as we only analysed 
prescribed drugs: Twenty percent of patients using NSAIDs buy them as over-the-
counter drugs (157),  making a higher prevalence of DDSIs with NSAIDs likely. 
To what extent GPs ask for over-the-counter drugs during their consultations and 
thus “prescribe cautiously” is poorly understood, but there is certainly room for 
improvement. 
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It is important to note that DDSIs are a direct consequence of single disease treat-
ment guidelines (94). This means that GPs who follow guidelines will inevitably 
induce PIP. The prevalence of DDSIs therefore only partly reflects the responsi-
bility of prescribing GPs, but rather the fact that guidelines do not meet the needs 
of multimorbid patients. Guidelines on the medical care of multimorbid older 
patients have been issued by the National Institute for Health and Care Excellence 
and The Royal college of GPs in UK (158, 159). Important suggestions are both 
a greater focus on the effectiveness of drug treatment and that the patient’s needs 
should be prioritized during a medication review. 
Finally, the presence of careful prescribing shown in our study may also be one 
explanation for the negative results of the multifaceted educational intervention 
(III). It evokes the question if there was enough potential to improve prescribing. 
However, the amelioration of clinical outcomes after an intervention aiming to 
reduce PIP (75) implies that there are still many possibilities to enhance appro-
priate prescribing.
6.2.3 Prescribing did not improve – why?
There are several studies using multifaceted educational approaches in primary 
care that showed a reduction of PIP (75) (table 3). We found neither a reduction 
of PIP nor unplanned healthcare. Major possible explanations are “complexity” 
and “dilution”.
6.2.3.1 Complexity
First, the definition of PIP may have been too complicated. It was based on the 
Swedish criteria and included five categories (polypharmacy, PIP in relation to 
renal function, drugs that should be avoided and anticholinergic drugs, drug-drug 
interactions and drug-disease interactions). During the educational sessions, we 
referred to certain of these PIP categories only in an ‘overarching’ manner as 
described in the methods part chapter 4.3.1. This information was too complex 
to be  useful for GPs and nurses (see paper III, appendix: powerpoint presentation 
shown  during educational session 1). We were for two reasons restricted as to the 
contents of the educational sessions: we should refer both to the Swedish criteria 
(54) as well as to the legislation defining two types of medication reviews: basic 
and comprehensive. Furthermore, the short time frame of 4 months to  prepare the 
trial did not permit us to weigh PIMs in relation to their prevalence in the  underlying 
population. Multifaceted educational studies in primary care that successfully 
improved prescribing (75, 129, 130) focused on 3-13 PIMs which probably is a 
major explanation for their positive results. 
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Second, complexity at different levels is reported by GPs and nurses participating 
in the educational sessions (IV) (figure 16). The clinical evaluation of older patients 
is complex, as chronic disease and side effects may cause the same symptoms. 
Furthermore, there is a narrow line between benefit and harm of certain drugs, 
such as ACE-inhibitors, as discussed in chapter 6.2.2. In such a context, it is a 
challenge to “improve” prescribing, which also explains the lack of effectiveness 
of our intervention.
Third, the working procedure for medication reviews which GPs and nurses 
were asked to fill out during the educational sessions may have been too complex 
(figure 14). The procedure was developed based on recommendations given in 
the official guidelines (150) and modified in relation to our clinical experience 
as GPs as well as relevant literature (27). As a consequence of their complexity, 
it is  uncertain to which extent medication reviews actually were implemented. 
Independent of whether medication reviews are performed in an in- or outpatient 
setting, their effects on clinical outcomes are more than doubtable (108) (109), 
which puts our findings in line with those of other researchers. Of note, only 
Dreischulte et al. (75) found an improvement of clinical outcomes. The limited 
number of PIMs and the regular (every 8th week) feedback may be the two most 
important explications for the decrease in drug-related admissions.
6.2.3.2 Dilution 
We measured the effects of the intervention in all older patients registered with 
the practice instead of in those having an appointment with the GP or receiving 
medication reviews. This implies that the study population was too unspecific.
Furthermore, too few GPs and nurses may have participated in the educational 
sessions. The information provided during the educational sessions reached a 
total of two thirds of the intended recipients. Regarding future interventions with 
educational outreach visits, it is important to assure high participation.
Finally, the use of register data implied that certain effects of the intervention 
could not be captured. For example, it is possible that physicians to a higher extent 
calculated renal function in their older patients after the intervention.
6.3 Strengths and limitations
6.3.1 Study design (I–IV)
In studies I and II, we were interested in how many patients were exposed to PIP 
 during the study period. A cross-sectional study is the design of choice when ana-
lysing a prevalence. 
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In study II, the cross-sectional design implied that drug exposure may have 
 happened before the appearance of the disease, meaning that we assessed adverse 
drug reactions rather than DDSIs. However, as the prevalence of mainly chronic 
disease was assessed during 2012-2016 and drug use during 2016 this is rather 
unlikely. Still, to give a more accurate picture the prevalence of DDSIs should be 
reassessed using a prospective approach.
Study III was a cluster-randomized controlled trial in 69 primary care practices. 
In view of the work load and costs that come along with the planning, perfor-
mance and analysis of such a trial the question arises if we should have chosen 
another study design, as evoked by one of the reviewers of paper III. An alterna-
tive approach might have been an observational before-after-analysis or a time 
series analysis. However, the level of evidence derived from observational studies 
is lower than from randomized trials. Moreover, the extra workload to randomise 
practices appeared manageable as the Stockholm County Council had decided 
that a campaign on PIP and medication reviews was to be launched with the task 
to visit all primary care practices. Ideally, a complex intervention should build on 
several steps: a preclinical theoretical step, a modelling phase, and an exploratory 
trial testing the feasibility of the intervention (160). Finally, a confirmative ran-
domized trial may be launched. Due to the time constraints we faced (described 
in chapter 4.3.1) it was not possible to follow this ideal working process, which 
may be a limitation. 
The multifaceted intervention did not improve PIP, which is why we decided to 
analyse the diaries the tutors had written after each education session (study IV). 
We were interested in GPs’ and nurses’ views on medication reviews and PIP in 
older patients and hoped to find hints to why the educational intervention had 
not produced the expected results. In this context, the diaries added important 
information. Documents such as diaries are valuable data sources in qualitative 
research and allow to generate hypotheses (161). However, interviews or focus 
groups with the participating GPs and nurses would have given us the possibility 
to ask follow-up questions and thus to gain deeper understandings. Still, due to 
time and financial constraints we were not able to collect such data.
6.3.2 Register data (I–III)
Feedback on prescribing derived from register data has previously successfully 
improved prescription patterns in the Stockholm region with 2.1 million inhabit-
ants (149, 162).
This was an important reason to use register data in studies I-III. Figure 19 shows 
other advantages but even disadvantages with the use of register data. 
46
high coverage
easy to collect
no recall bias
no selecon bias
different registers may be linked with
personal identy number
validity of diagnoses?
no clinical data 
such as blood pressure, symptoms
purchase vs. intake of drugs?
no over-the-counter drugs
quality of documentaon depends on:
GPs´ work load, reimbursement issues
Figure 19. Advantages and disadvantages with the use of register data in studies I-III.
A complete documentation and registration of diagnoses and procedures is a pre-
requisite for reimbursement and assures high coverage. Moreover, register data 
are neither prone to recall nor selection bias and are easy to collect. In Sweden, 
register data may be linked via the personal identity number. However, data quality 
depends to some extent on healthcare professionals’ work load and reimbursement 
issues which may induce registration bias. In study III, the financial incentives 
linked to the registration of medication reviews (143) may explain why there was 
no difference in the number of registered medication reviews between interven-
tion and control practices. 
The validity of coded diagnoses may differ. A systematic review from 2010 includ-
ing 132 published articles concluded that hospital diagnoses derived from the 
National Patient Register have a high validity (143). However, for some diagnoses 
the sensitivity is lower, such as hypertension and hyperlipidemia. Patients with 
these diagnoses are rather followed up in primary care and outpatient settings. The 
coding of chronic diseases such as diabetes, hypertension (163) and heart failure 
(164) in primary care may be trusted; however, only few validation studies on 
diagnoses coded in primary care have been done, and in particular the validity of 
more uncommon diagnoses has not been sufficiently studied. Still, as we consid-
ered diagnoses that had been registered at all three sectors of healthcare, hospital, 
outpatient specialists and primary care, we believe that our findings are valid.
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The validity of the prescribed drug register from which we collected dispensation 
data is high (144). However, the lack of clinical data and information on dispensa-
tion rather than intake of drugs is a limitation. For example, we were not able to 
correctly assess the DDSI “verapamil or diltiazem with NYHA Class III or IV heart 
failure” (37) as the NYHA class is not registered in a structured way. In study I, 
the mean-Defined Daily Dose for one third of dispensed C-substances could not 
be calculated due to the lack of clinical or laboratory information, implying an 
underestimation of the prevalence of excessive dosing. On the other hand, meas-
uring dispensation rather than intake of drugs may imply an overestimation of 
PIP, as patients may stop taking a dispensed drug if they experience side effects. 
Finally, we only had access to prescription drugs but not over-the-counter drugs 
such as NSAIDs. This may have led to a substantial underestimation of both the 
prevalence of PIP in relation to renal function and drug-disease interactions.
6.3.3 Renal function (I)
Drug dosing guidelines have historically relied on Cockcroft-Gault formula (165). 
Janusmed recommends to use Lund-Malmö-formula for eGFR calculation which 
is a revised formula of CKD-EPI (166). In accordance with updated international 
recommendations (167) we used CKD-EPI formula. Compared to Cockcroft-Gault, 
CKD-EPI underestimates the prevalence of renal impairment (168) which may 
also imply an underestimation of the prevalence of PIP in relation to renal function. 
On the other hand, a sensitivity analysis performed by Chang et al (153) did not 
reveal important differences regarding the prevalence of renal PIMs when using 
Cockcroft-Gault vs. CKD-EPI. As a consequence, it is uncertain if the use of CKD-
EPI rather than Cockcroft-Gault had significant impact on the observed prevalence.
Of note, we included only those patients whose creatinine had been measured (I). 
The disease burden in such patients may be higher than in the average older popula-
tion. However, even the opposite is possible: patients without creatinine assessment 
are more frequently exposed to PIP in relation to renal function, because the GP 
is not aware of the impairment of renal function. Still, substantial selection bias 
seems unlikely as the large majority (95%) of older patients in another Swedish 
primary care population had their creatinine value checked [33].
6.3.4 Diaries as a data source (IV)
The diaries the tutors presented for the research group were unexpectedly rich and 
extensive. Four questions in relation to their validity arose.
1) In research, is it approved to qualitatively analyse data that have not been 
planned to be qualitatively analysed already from the beginning? Yes, in 
document analysis it may be: “Documents contain text (words) and images 
that have been recorded without a researcher’s intervention.” (quoted from 
(161)). 
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2) How trustworthy is information that is retrieved from documents whose 
collection has not been done for research purposes? “Documents of all 
types can help the researcher uncover meaning, develop understanding, 
and discover insights relevant to the research problem” (quoted from (169)). 
Findings retrieved from the qualitative analysis of documents should not 
be overstated but may be used to create hypotheses.
3) Are the diaries biased? It is unlikely that the tutors reported selectively, 
as they were not aware that the diaries would be analysed. Moreover, the 
diaries were written with the purpose to document what had been discussed 
during the sessions thus recording the pedagogical process and allowing 
a natural starting point for the follow up session. Documenting selectively 
would thus have impeded the usefulness of the diaries for the tutors.
4) Which qualitative approach should be chosen to analyse the diaries? We 
considered that thematic analysis would match our aim and also the character 
of our data material, as this approach permits to identify patterns in views, 
to discover similarities and differences in views, and to create hypotheses 
(170).
6.3.5 Definition of potentially inappropriate prescribing (I-III)
PIP in relation to renal function were defined with reference to Renbase®, a 
knowledge-database that relies on a thorough review of published literature. There 
were two reasons to choose Renbase®. First, it has a very inclusive approach to PIP 
in relation to renal function, comprising contraindicated drugs as well as dosing 
recommendations. Renbase® contains in its version from 2016 recommendations 
on more than 400 substances for CKD stage 3 or 4. Second, Swedish healthcare 
professionals consult this source when performing medication reviews in older 
patients (59). However, from a scientific point of view it must be criticized that 
Renbase® is not free of charge, which makes it impossible for interested readers 
to scrutinize the recommendations. 
We derived 31 DDSIs from STOPP-START criteria (37) which have a high clini-
cal validity (42). Five DDSIs could not be assessed by means of register data. The 
clinical relevance of certain STOPP-DDSIs may be questioned, such as the deterio-
ration of hypertension in patients who receive NSAIDs (171). Interestingly, Beers 
criteria do not include this DDSI. As hypertension/NSAID explained more than 
75% of the overall prevalence it would have changed our findings substantially if 
we had used Beers criteria instead of STOPP-START. 
In study III, PIP was defined in relation to the Swedish criteria (54). Important 
differences between the Swedish criteria and STOPP-START criteria are shown 
in table 1. The main concern is that they are not validated prospectively, meaning 
that it is unsure if they are associated with drug-related morbidity. However, as 
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study III was performed in the context of an official campaign (chapter 4.3.1 and 
box 1 in article III), we were restricted to certain contents of the educational ses-
sions, such as to refer to medication reviews according to the legislation (151) as 
well as to define PIP in relation to the Swedish criteria (54).
6.4 How may the findings be useful for general 
 practitioners and nurses?
During a medication review, it is important to consider renal function and to adapt 
drug use accordingly. The most important drug groups to account for are NSAIDs, 
antidiabetics, drugs acting on RAAS, and opioids. If the eGFR is below 30ml/min, 
even simvastatin and zopiclone doses should be controlled. Computerized deci-
sion support tools may help to identify PIP in relation to renal function in patients 
using drugs that are less commonly prescribed.
Drug-disease interactions are less frequent than PIP in relation to renal function. 
However, if an older patient has cardiovascular disease, benign prostatic hyper-
plasia, urinary incontinence or dementia, GPs should be proactive and check for 
drugs that worsen concomitant diseases. Of note, NSAIDs are commonly impli-
cated in PIP. They should only rarely be prescribed. As they are over-the-counter 
drugs, GPs and nurses should actively inquire their use. 
GPs and nurses should be proactive and ask for education on PIP in older patients 
and feedback on prescribing, as both have the potential to improve prescribing. In 
Stockholm County, GPs and nurses may use the services offered by the Regional 
Drug Committee (162). Furthermore, the use of multimorbidity guidelines should 
be encouraged, and physicians should actively participate in the development of 
such guidelines, in order to assure their clinical usefulness. During medication 
reviews, benefits and harms of drugs should be weighted against each other. GPs 
and nurses should discuss all prescribing with their older patients and take into 
account the patients’ drug treatment goals. 
6.5 Future perspectives
6.5.1 Understanding
Qualitative research should be performed. It is important to understand more about 
older patients’ views on their drug treatment. It should be elucidated what expec-
tations they have in relation to the goals of drug treatment, and how primary care 
may meet these expectations. Furthermore, healthcare professionals who work 
with older multimorbid patients should be asked which kind of support they need 
in relation to prescribing. Interventions addressing PIP should be based on the 
needs of patients and healthcare professionals.
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6.5.2 How common?
There is a need for increased knowledge on the actual harm of PIP. Several PIP 
criteria such as Beers (29) do not seem to predict clinical outcomes to a sufficient 
extent. In view of the time constraints GPs and nurses in primary care face, but 
even in relation to shared-decision making with older patients it is important to 
determine which PIMs really cause harm. 
6.5.3 How to address?
There is no simple answer to how prescribing in older patients may be improved. 
Former interventional studies in primary care with the aim to improve  prescribing 
in this patient group have shown negative or only decently favorable results. There 
is a need for multifaceted interventions in primary care combining several evidence-
based implementation strategies such as feedback on prescribing and education on 
multimorbidity guidelines and PIP. Healthcare administrative data are a valuable 
data source to create feedback on prescribing that focuses on common and severe 
PIP. Furthermore, clinically relevant outcomes have to be defined and assessed, such 
as improvement of symptoms, attainment of patient-defined drug treatment goals, 
patient satisfaction with drug treatment, and reduction of drug-related morbidity 
and unplanned healthcare. PIP is only a process outcome and should be interpreted 
cautiously, taking into account if shared decision-making has taken place.
It is primary care’s mission to offer medical care to the growing group of older 
multimorbid patients. Stakeholders need to emphasize primary care’s authority 
in relation to other healthcare givers. This is particularly important in view of the 
uncertainty among GPs regarding their responsibility for the entire drug list. Last 
but not least, primary care needs financial support in order to meet the medical 
needs of older multimorbid patients.
6.6 Every coin has two sides
During the course of this research project and during my clinical work with older 
patients in primary care I have encountered many coins with two sides indeed 
(figure 20).
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Figure 20. Every coin has two sides. PIP potentially inappropriate prescribing.
The line between benefit and harm of a drug is narrow, as shows the example of 
enalapril in a patient with heart and renal failure. To weight benefit against harm 
and to differentiate if symptoms rely on the disease or the drug are major challenges. 
To make decisions in close communication with patients is important, but may 
put me in the awkward position to continue harmful drug treatment “because the 
patient wants it”. Finally, approaches to address PIP in older patients take their 
departure from the whole drug list (such as medication reviews) or, on the other 
hand, from a selection of potentially inappropriate medications. Both approaches 
have advantages and disadvantages and should presumably be combined.
6.7 Conclusions
Potentially inappropriate prescribing in relation to renal function is found in every 
second to third older patient with impaired renal function in primary care. Excessive 
dosing was more common than the use of contraindicated drugs. Drug-disease 
interactions were seen in every tenth older patient, with a predominance of NSAIDs. 
In general, only a few drugs accounted for the majority of PIP, such as NSAIDs, 
drugs acting on the renin-angiotensin-aldosterone system, antidiabetics and opioids. 
Medication reviews that address PIP in its entirety are difficult to implement in 
primary care and may not improve prescribing in older patients. GPs and nurses 
expressed their concern that the complexity of care of older patients as well as 
PIP are a major challenges. They feel that their efforts to achieve appropriate pre-
scribing are undermined by this complexity. 
In view of the risks of PIP in older patients it is necessary to continue research 
into how prescribing may be improved. 
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7 EPILOGUE
One year ago, her eGFR had been 44 ml/min, but since then her creatinine had 
not been checked. I asked her to pass by the laboratory and ordered even a blood 
glucose and hemoglobin level. My plan was to increase the dose of enalapril in 
case her renal function would allow to do so. This would hopefully improve her 
heart function and even nycturia. Could I even reduce the dose of her diuretics, 
in case they worsened her incontinence? I shared my ideas with her. She agreed 
to a blood sample but was against changes of her heart treatment. “In hospital the 
doctor increased my heart medicine and the next day I fell because I was so dizzy! 
No, don’t give me more medicines, leave it as it is.”
Looking on my watch I realized that we had overrun the consultation time by four 
minutes. “Would it be okay for you to meet the nurse next week? I would like 
her to go through all your medicines, and to discuss if you have any difficulties 
in taking them”. I shared the daughters’ concerns about her getting forgetful, and 
wanted to make sure that she was capable to follow her medication regime. “I will 
give you a new appointment in four weeks to follow up on your complaints!”
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